Status:
COMPLETED
Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch
Lead Sponsor:
Novartis
Conditions:
Allergic Rhinoconjunctivitis
Eligibility:
All Genders
12-70 years
Phase:
PHASE3
Brief Summary
This study will assess efficacy and safety of intraseasonal specific short-term immunotherapy with Depiquick® Birch in patients with allergic rhinitis and or rhinoconjunctivitis with or without interm...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients must experience significant allergic symptoms on visit 2
- Medical history of allergic rhinitis and/or rhinoconjunctivitis with clinically relevant sensitization to tree allergens
- Specific IgE against birch allergens (CAP RAST ≥ 2)
- Exclusion criteria:
- History of significant clinical manifestations of allergy as a result of sensitization against grass or weed pollen and perennial allergens
- FEV1 or PEF value ≤ 80 %
- Persistent asthma (GINA ≥ 2)
- Other protocol-defined inclusion/exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT01902992
Start Date
March 1 2012
End Date
July 1 2012
Last Update
March 22 2017
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Aachen, Germany, 52074
2
Novartis Investigative Site
Aschaffenburg, Germany, 63739
3
Novartis Investigative Site
Augsburg, Germany, 86179
4
Novartis Investigative Site
Bad Wildbad, Germany, 75323